Group by Gene: CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Tyrosine Kinase Inhibitors EGFR BCL Inhibitors Chemotherapy DNA | DNA synthesis inhibitor gemcitabine | cisplatin | PD1 inhibitor nivolumab | pembrolizumab | DNA synthesis inhibitor, Thymidylate synthase inhibitor capecitabine + mitomycin | 5-fluorouracil + mitomycin | EGFR inhibitor erlotinib | VEGF-A inhibitor bevacizumab | Tubulin polymerization promoter carboplatin | TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor larotrectinib | GC | Chemotherapy FP | CP | CaT | Tubulin polymerization promoter, Bcl2 inhibitor paclitaxel | TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor entrectinib |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||
PD-L1 overexpression | ||||||||||||||||
PD-L1 negative | ||||||||||||||||
PD-L1 expression | ||||||||||||||||
NTRK3 fusion | ||||||||||||||||
NTRK1 fusion | ||||||||||||||||
NTRK2 fusion | ||||||||||||||||
TMB-H | ||||||||||||||||
MSI-H/dMMR |